RenovoRx Inc. has provided an update on the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue through the third quarter of 2025. The company has expanded its customer base from five to fourteen cancer centers, with quotes delivered to an additional ten centers and ongoing discussions with dozens more. RenovoRx is targeting an initial potential peak annual U.S. revenue opportunity of around $400 million for RenovoCath as a stand-alone device, with opportunities to expand into additional applications. Enrollment in its ongoing clinical study is expected to be completed in the first half of 2026, with final data anticipated in 2027. The company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is being positioned to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. You can access the full presentation through the link below. https://renovorx.com/for-clinicia

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.